These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 20053161)

  • 1. Enzyme induction: translating multiple approaches, assays, endpoints, and opinions into a valuable induction screening strategy.
    Fretland A; Monshouwer M
    Comb Chem High Throughput Screen; 2010 Feb; 13(2):135-44. PubMed ID: 20053161
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current industrial practices in assessing CYP450 enzyme induction: preclinical and clinical.
    Sinz M; Wallace G; Sahi J
    AAPS J; 2008 Jun; 10(2):391-400. PubMed ID: 18686044
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High-throughput screening approaches for investigating drug metabolism and pharmacokinetics.
    Roberts SA
    Xenobiotica; 2001; 31(8-9):557-89. PubMed ID: 11569526
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metabolism profiling, and cytochrome P450 inhibition & induction in drug discovery.
    Yan Z; Caldwell GW
    Curr Top Med Chem; 2001 Nov; 1(5):403-25. PubMed ID: 11899105
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CYP induction-mediated drug interactions: in vitro assessment and clinical implications.
    Lin JH
    Pharm Res; 2006 Jun; 23(6):1089-116. PubMed ID: 16718615
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Experimental models for evaluating enzyme induction potential of new drug candidates in animals and humans and a strategy for their use.
    Thompson TN
    Adv Pharmacol; 1997; 43():205-29. PubMed ID: 9342178
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High-throughput fluorescence assay for cytochrome P450 mechanism-based inactivators.
    Kenaan C; Zhang H; Hollenberg PF
    Methods Mol Biol; 2013; 987():61-9. PubMed ID: 23475667
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Implications and consequences of enzyme induction on preclinical and clinical drug development.
    Worboys PD; Carlile DJ
    Xenobiotica; 2001; 31(8-9):539-56. PubMed ID: 11569525
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Managing the Risk of CYP3A Induction in Drug Development: A Strategic Approach.
    Jones BC; Rollison H; Johansson S; Kanebratt KP; Lambert C; Vishwanathan K; Andersson TB
    Drug Metab Dispos; 2017 Jan; 45(1):35-41. PubMed ID: 27777246
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Induction of cytochrome P450 enzymes: a view on human in vivo findings.
    Hukkanen J
    Expert Rev Clin Pharmacol; 2012 Sep; 5(5):569-85. PubMed ID: 23121279
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Induction of drug metabolizing enzymes: a survey of in vitro methodologies and interpretations used in the pharmaceutical industry--do they comply with FDA recommendations?
    Hewitt NJ; de Kanter R; LeCluyse E
    Chem Biol Interact; 2007 May; 168(1):51-65. PubMed ID: 17239835
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Computational approaches for predicting CYP-related metabolism properties in the screening of new drugs.
    Crivori P; Poggesi I
    Eur J Med Chem; 2006 Jul; 41(7):795-808. PubMed ID: 16644065
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro ADME profiling using high-throughput rapidfire mass spectrometry: cytochrome p450 inhibition and metabolic stability assays.
    Wu X; Wang J; Tan L; Bui J; Gjerstad E; McMillan K; Zhang W
    J Biomol Screen; 2012 Jul; 17(6):761-72. PubMed ID: 22460176
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metabolic enzyme microarray coupled with miniaturized cell-culture array technology for high-throughput toxicity screening.
    Lee MY; Dordick JS; Clark DS
    Methods Mol Biol; 2010; 632():221-37. PubMed ID: 20217581
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Screening of drug candidates for their drug--drug interaction potential.
    Rodrigues AD; Lin JH
    Curr Opin Chem Biol; 2001 Aug; 5(4):396-401. PubMed ID: 11470602
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Automated triplexed hepatocyte-based viability and CYP1A and -3A induction assays.
    Larson B; Moeller T; Banks P; Cali JJ
    J Biomol Screen; 2011 Sep; 16(8):895-902. PubMed ID: 21693767
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of models for predicting drug-drug interactions due to induction.
    Fahmi OA; Ripp SL
    Expert Opin Drug Metab Toxicol; 2010 Nov; 6(11):1399-416. PubMed ID: 20955108
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Luciferin IPA-based higher throughput human hepatocyte screening assays for CYP3A4 inhibition and induction.
    Doshi U; Li AP
    J Biomol Screen; 2011 Sep; 16(8):903-9. PubMed ID: 21832258
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessment of drug-drug interactions: concepts and approaches.
    Weaver RJ
    Xenobiotica; 2001; 31(8-9):499-538. PubMed ID: 11569524
    [TBL] [Abstract][Full Text] [Related]  

  • 20. "Cocktail" approaches and strategies in drug development: valuable tool or flawed science?
    Zhou H; Tong Z; McLeod JF
    J Clin Pharmacol; 2004 Feb; 44(2):120-34. PubMed ID: 14747420
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.